Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 62013CN0210

Kawża C-210/13: Talba għal deċiżjoni preliminari mressqa mill-High Court of Justice (Chancery Division) (ir-Renju Unit) fit- 18 ta’ April 2013 — Glaxosmithline Biologicals SA, Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG vs Comptroller-General of Patents, Designs and Trade Marks

ĠU C 189, 29.6.2013, p. 8–8 (BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

29.6.2013   

MT

Il-Ġurnal Uffiċjali tal-Unjoni Ewropea

C 189/8

Talba għal deċiżjoni preliminari mressqa mill-High Court of Justice (Chancery Division) (ir-Renju Unit) fit-18 ta’ April 2013 — Glaxosmithline Biologicals SA, Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG vs Comptroller-General of Patents, Designs and Trade Marks

(Kawża C-210/13)

2013/C 189/15

Lingwa tal-kawża: l-Ingliż

Qorti tar-rinviju

High Court of Justice (Chancery Division)

Partijiet fil-kawża prinċipali

Rikorrenti: Glaxosmithline Biologicals SA, Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG

Konvenut: Comptroller-General of Patents, Designs and Trade Marks

Domandi preliminari

(1)

Adjuvant li waħdu ma għandux effett terapewtiku iżda li jsaħħaħ l-effett terapewtiku ta’ antiġen meta jkun ikkombinat ma’ dan l-antiġen f’vaċċin, huwa “ingredjent attiv” fis-sens tal-Artikolu 1(b) tar-Regolament (KE) Nru 469/2009/KE (1)?

(2)

Fil-każ ta’ risposta negattiva għall-ewwel domanda, tista’ kombinazzjoni ta’ tali adjuvant ma’ antiġen madankollu tiġi kkunsidrata bħala “kombinazzjoni ta’ ingredjenti attivi” fis-sens tal-Artikolu 1(b) tar-Regolament (KE) Nru 469/2009/KE?

(1)  Regolament (KE) Nru 469/2009 tal-Parlament Ewropew u tal-Kunsill, tas-6 ta’ Mejju 2009, dwar iċ-ċertifikat ta’ protezzjoni supplimentari għal prodotti mediċinali (ĠU L 152, p. 1).

Top